NCT00469976撤回2 期
Phase II Trial of Enzastaurin Plus Carboplatin and Gemcitabine (ECoG) in Bevacizumab-Ineligible Patients and Enzastaurin Plus Carboplatin, Gemcitabine and Bevacizumab (B-ECoG) in Bevacizumab-Eligible Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Progression-free survival at 6 months (group 1)
研究概览
简要总结
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving enzastaurin together with carboplatin and gemcitabine, with or without bevacizumab, may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving enzastaurin together with carboplatin and gemcitabine, with or without bevacizumab, works in treating patients with recurrent, stage IIIB, or stage IV non-small cell lung cancer.
详细描述
OBJECTIVES:
Primary
- Determine the progression-free survival in patients with recurrent or stage IIIB or IV non-small cell lung cancer treated with carboplatin, gemcitabine, and enzastaurin with or without bevacizumab.
Secondary
- Determine the toxicity of this regimen in these patients.
- Determine the overall survival in patients treated with this regimen.
- Determine the response rate in patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
- •Stage IIIB (with confirmed malignant pleural effusion), stage IV, or recurrent disease
- •Mixed tumors categorized by the predominant cell type are allowed provided no small cell elements exist
- •Cytologic or histologic elements can be established on metastatic tumor aspirates or biopsy
- •Measurable disease as defined by RECIST criteria
- •No squamous cell carcinoma (group 1)
- •No history of brain metastases (group 1)
- •History of treated brain metastases allowed provided patient is not taking steroids and anti-seizure mediation (group 2)
- •PATIENT CHARACTERISTICS:
- •ECOG performance status 0-1
- •ANC ≥ 1,500/mm³
- •Platelet count ≥ 100,000/mm³
- •Bilirubin ≤ 1.5 mg/dL
- •Creatinine ≤ 1.5 times upper limit of normal (ULN)
- •Alkaline phosphatase ≤ 3 times ULN (≤ 5 times ULN with liver metastases)
- •AST and ALT ≤ 3 times ULN (≤ 5 times ULN with liver metastases)
- •INR < 1.5 or PTT normal (group 1)
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception during (groups 1 and 2) and for 6 months after completion of study treatment (group 1)
- •No preexisting peripheral neuropathy ≥ grade 2
- •Must be able to swallow tablets
- •No cardiovascular condition, including any of the following:
- •Myocardial infarction within the past 6 months
- •Cerebrovascular ischemia or stroke within the past 6 months
- •NYHA congestive heart failure > class II
- •Unstable angina pectoris
- •Serious cardiac arrhythmia requiring medication
- •Significant vascular disease
- •Symptomatic peripheral vascular disease
- •No concurrent medical condition, psychiatric illness, or limitations that would limit study compliance
- •No ongoing active infection or ongoing fever within the past 6 months
- •No history of uncontrolled hypertension, defined as blood pressure ≥ 150/90 mm Hg despite being on a stable regimen of anti-hypertensive therapy
- •No serious nonhealing wound, ulcer, or bone fracture within the past 4 weeks
- •No ongoing or active infection
- •No history of thrombotic or hemorrhagic disorders, bleeding diathesis, or coagulopathy (group 1)
- •No bleeding > grade 2 or any bleeding requiring intervention within the past 4 weeks (group 1)
- •No history of gross hemoptysis (defined as > ½ teaspoon of bright red blood) (group 1)
- •Urine protein:creatinine (UPC) ratio < 1.0 by spot urinalysis
- •For UPC ratio > 0.5, a 24-hour urine protein must be obtained and the urine protein level must be < 1,000 mg (group 1)
- •None of the following conditions (group 1):
- •Grade II or greater peripheral vascular disease
- •Abdominal fistula
- •Gastrointestinal perforation
- •Intra-abdominal abscess
- •No known hypersensitivity to any component of bevacizumab (group 1)
- •No history of hypertensive crisis or hypertensive encephalopathy (group 1)
- •PRIOR CONCURRENT THERAPY:
- •More than 4 weeks since prior major surgical procedure
- 另有 13 项未显示
排除标准
- 未提供
结局指标
主要结局
Progression-free survival at 6 months (group 1)
Progression-free survival at 4.5 months (group 2)
次要结局
未报告次要终点
研究者
相似试验
已完成
2 期
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerPrimary Peritoneal Cavity CancerOvarian CancerNCT00407758Gynecologic Oncology Group28
已完成
1 期
Enzastaurin in Treating Young Patients With Refractory Primary CNS TumorsBrain and Central Nervous System TumorsNeuroblastomaNCT00503724Pediatric Brain Tumor Consortium32
Unknown
1 期
Enzastaurin and Temozolomide in Treating Patients With Primary GliomasBrain and Central Nervous System TumorsNCT00516607European Organisation for Research and Treatment of Cancer - EORTC28
已完成
1 期
Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00550927Eli Lilly and Company42
已完成
2 期
A Study of Enzastaurin in Participants With Follicular LymphomaLymphoma, FollicularNCT00475644Eli Lilly and Company66